Results 231 to 240 of about 38,769 (305)

Pharmacokinetics of Bexagliflozin After Intravenous and Oral Administration in Cats

Journal of Veterinary Pharmacology and Therapeutics, EarlyView.
ABSTRACT Bexagliflozin, a selective sodium–glucose cotransporter 2 (SGLT2) inhibitor, has been developed for feline diabetes mellitus. This study characterized bexagliflozin pharmacokinetics in healthy cats after single intravenous and oral administrations.
Yogini Patel, Sheeva Bhattarai, Céline E. Toutain   +2 more
wiley   +1 more source

Comparative Clinical Analysis of DPP-4 inhibitors and SGLT2 Inhibitors: A Real-World Switch Study. [PDF]

J Obes Metab Syndr
Choe HJ, Kwak MK, Lee JW, Choi YM, Hong EG.   +4 more
europepmc   +1 more source

Low Weight Loss Response to Incretin Analogs: A Systematic Review

Obesity Reviews, EarlyView.
ABSTRACT The development of GLP‐1 and GIP analogs has been a significant breakthrough in type 2 diabetes and obesity pharmacotherapy. However, individual responses to these medications can vary widely. This systematic review examines factors associated with low or no weight loss response to GLP‐1 and GIP analogs. Key predictors of poor response include
Pamela S. Gaskin, Peter S. Chami
wiley   +1 more source

Impact of SGLT2 Inhibitors on Clinical Outcomes in Patients with Diabetes Mellitus Following Heart Transplantation: A Meta-analysis. [PDF]

Diabetes Ther
Wang H, Xie X, Gong G, Huang L, Tang Z.
europepmc   +1 more source

Innovations in Obesity Treatment: Beyond Adipose Tissue Dysfunction

Obesity Reviews, EarlyView.
Obesity drives chronic inflammation, insulin resistance, type 2 diabetes, and cancer development through adipocyte dysfunction. Addressing this multisystemic disorder requires integrated strategies beyond diet and exercise, such as thermogenesis activation via menthol or capsinoids and appetite control through GLP‐1/GIP agonists and neuromodulation to ...
Jesica Martínez‐Godfrey, Irene Pomares‐Bri, Paula de Juan‐Maciá, Mariló Olivares‐Vicente, Enrique Barrajón‐Catalán, Vicente Micol, Enrique Roche, María Herranz‐López   +7 more
wiley   +1 more source

Precision Prescribing of SGLT2 Inhibitors in Individuals With Type 2 Diabetes for Primary Prevention of Heart Failure: Model Development and Validation Study. [PDF]

Diabetes Care
Young KG, McGovern AP, Hopkins R, Jansz TT, Cardoso PM, Holman RR, Pearson ER, Hattersley AT, Jones AG, Docherty K, Sattar N, Shields BM, Dennis JM, MASTERMIND Consortium.   +13 more
europepmc   +1 more source

Improved Glucagon Sensitivity Following Weight Loss: A Systematic Review and Meta‐Analysis

Obesity Reviews, EarlyView.
ABSTRACT Objective This systematic review and meta‐analysis investigated the effect of weight loss in people with obesity on two biomarkers of glucagon resistance: fasting plasma glucagon and alanine. Methods A comprehensive search was conducted in Medline and Embase. Random‐effects meta‐analyses and correlation analyses were performed.
Hye‐Rin Charlotte Kim, Lima Hamidi, Anne Majumdar, Matyas Fehervari, Emma Rose McGlone   +4 more
wiley   +1 more source

Another pleiotropic effect of SGLT2 inhibitors: Is it a new frontier in thyroid function regulation? [PDF]

Thyroid Res
Szklarz M, Wołos-Kłosowicz K, Szulc J, Górny J, Modzelewski R, Matuszewski W.   +5 more
europepmc   +1 more source

Drug‐Induced Sialolithiasis—A Big‐Data Retrospective Study

Oral Diseases, EarlyView.
ABSTRACT Background Sialolithiasis pathophysiology is multifactorial, with systemic medications often hypothesised as a key contributor, particularly in older adults (Drug‐Induced Sialolithiasis). However, robust evidence supporting this theory is limited.
Gal Avishai, Gil Caspi, Akhilanand Chaurasia, Gavriel Chaushu, Daya Masri, Ehud Jonas   +5 more
wiley   +1 more source